From: The costs, health and economic impact of air pollution control strategies: a systematic review
Country setting | Total | Positive cost–benefit | Partial positive cost–benefit*** | Negative cost–benefit |
---|---|---|---|---|
HICs | 47 | 34 | 7 | 6 |
LMICs | 48 | 29 | 13 | 6 |
Mixed regions | 9 | 9 | 0 | 0 |
Year of publication | ||||
From inception to 2012 | 30 | 26 | 3 | 1 |
2013–2022 | 74 | 46 | 18 | 10 |
Typology of air control strategies | ||||
Outdoor interventions | 75 | 54 | 13 | 8 |
Indoor interventions | 21 | 15 | 4 | 2 |
Mixed interventions | 8 | 3 | 4 | 1 |
Pollution control method | ||||
Source reduction | 42 | 26 | 10 | 6 |
End-of-pipe treatment | 15 | 11 | 4 | 0 |
Mixed methods | 17 | 9 | 6 | 2 |
Not specified | 30 | 26 | 1 | 3 |
Pollutant strategies | ||||
Single pollutant strategy | 51 | 39 | 8 | 4 |
Multi-pollutant strategy | 48 | 32 | 11 | 5 |
Not specified | 5 | 4 | 1 | 0 |
Pollutants targeted* | ||||
PM (PM2.5, PM10 and other forms) | 84 | 61 | 16 | 7 |
O3 | 19 | 16 | 2 | 1 |
NOX | 34 | 19 | 9 | 6 |
SOX | 32 | 17 | 12 | 3 |
Health related endpoints* | ||||
Premature deaths | 53 | 40 | 8 | 5 |
Restricted activity days | 18 | 14 | 2 | 2 |
Cardiovascular disease | 43 | 31 | 6 | 6 |
Asthma | 14 | 10 | 1 | 3 |
COPD | 22 | 16 | 3 | 3 |
Lung cancer | 21 | 13 | 4 | 4 |
Other respiratory diseases** | 44 | 34 | 7 | 3 |
Other health endpoints and not specified | 13 | 9 | 2 | 2 |